Lenvatinib

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced gastroesophageal adenocarcinoma, according to the agents’ manufacturers.

The addition of lenvatinib and pembrolizumab to transarterial chemoembolization extended PFS for patients with intermediate-stage hepatocellular carcinoma, according to randomized phase 3 study results.

Belzutifan significantly improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma, according to results of a randomized phase 3 trial.

Two phase 3 trials evaluating a regimen containing pembrolizumab plus lenvatinib for treatment of metastatic non-small cell lung cancer failed to meet their primary endpoints, according to the manufacturers of each agent.

A combination of lenvatinib and pembrolizumab continued to provide a greater survival benefit than sunitinib among patients with advanced renal cell carcinoma, an updated analysis of the randomized phase 3 CLEAR study showed.

SAN FRANCISCO — Lenvatinib plus pembrolizumab did not demonstrate a positive benefit-risk ratio compared with pembrolizumab and placebo as first-line therapy for certain patients with advanced urothelial carcinoma, study results showed.

Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with advanced endometrial cancer, according to randomized, phase 3 trial results published in The New England Journal of Medicine.

Lenvatinib plus transarterial chemoembolization prolonged survival and improved response rates among patients in China with advanced hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

The FDA approved the combination of pembrolizumab and lenvatinib for first-line treatment of adults with advanced renal cell carcinoma.

The FDA granted regular approval to the combination of pembrolizumab and lenvatinib for certain women with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.